# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION MEMORANDUM ASSAY ONLY TEMPLATE

A. 510(k) Number: k141689   
B. Purpose for Submission: New assay   
C. Measurand: C-reactive protein (CRP)   
D. Type of Test: Quantitative   
E. Applicant: Qualigen, Inc.

# F. Proprietary and Established Names:

FastPack High Sensitivity C-Reactive Protein Immunoassay FastPack High Sensitivity C-Reactive Protein Calibrator Kit FastPack High Sensitivity C-Reactive Protein Controls FastPack High Sensitivity C-Reactive Protein Method Verification Kit

# G. Regulatory Information:

1. Regulation section:

21 CFR 866.5270 – C-reactive protein immunological test system   
21 CFR 862.1150 – Calibrator   
21 CFR 862.1660 – Quality Control Material (Assayed and Unassayed)

2. Classification:

Class II   
Class II   
Class I, reserved

3. Product code:

DCK – C-reactive, protein, Antigen, Antiserum JIT – Calibrator, Secondary JJX – Quality Control Material (Assayed and Unassayed)

4. Panel: Clinical Chemistry

# H. Intended Use:

1. Intended use(s): See indication for use.

2. Indication(s) for use:

FastPack High Sensitivity C-Reactive Protein Immunoassay FastPack High Sensitivity C-Reactive Protein Immunoassay is to be used for evaluation of conditions thought to be associated with inflammation, in otherwise healthy individuals. The FastPack High Sensitivity C-Reactive Protein Immunoassay is intended for use with the FastPack Analyzer. Not intended for Point-of-Care use.

FastPack High Sensitivity C-Reactive Protein Calibrator Kit   
FastPack High Sensitivity C-Reactive Protein Calibrators are used for calibrating the quantitative FastPack High Sensitivity C-Reactive Protein Immunoassay on the FastPack Analyzer.

FastPack High Sensitivity C-Reactive Protein Controls FastPack High Sensitivity C-Reactive Protein Controls are used for quality control of the FastPack High Sensitivity C-Reactive Protein Immunoassay on the FastPack Analyzer.

FastPack High Sensitivity C-Reactive Protein Method Verification Kit FastPack High Sensitivity C-Reactive Protein Verifiers are used in the quantitative verification of calibration and assay range of the quantitative FastPack High Sensitivity C-Reactive Protein Immunoassay on the FastPack Analyzer.

3. Special conditions for use statement(s):

For prescription use only.   
For in vitro diagnostic use only.   
Not intended for Point-of-Care use.

4. Special instrument requirements:

FastPack Analyzer

# I. Device Description:

Each FastPack High Sensitivity C-Reactive Protein Immunoassay Kit contains: · 30 FastPack High Sensitivity C-Reactive Protein Reagent Packs · Sample diluent A, 32 vials, $2 . 4 7 5 \mathrm { m l }$ each

Each FastPack High Sensitivity C-Reactive Protein Reagent Pack contains:

Paramagnetic Particles coated with streptavidin, 150 1-JL Murine monoclonal anti-CRP antibody covalently linked to alkaline phosphatase and Murine monoclonal anti-CRP antibody covalently linked to biotin, 100 1-JL Wash Buffer, $2 . 0 \mathrm { m l }$ Tris buffer containing surfactants · Substrate, 145 1-JL lmmuGlow: lndoxyl-3-phosphate and lucigenin in buffer containing preservatives

The test reagents include:

· Conjugate solution – · a murine monoclonal anti-C-reactive protein (CRP) monoclonal antibody conjugated to alkaline phosphatase · a biotinylated murine monoclonal anti-CRP monoclonal antibody

· Solid support streptavidin coated paramagnetic particles

Substrate solution – ImmuGlow · Wash solution: Tris buffer containing detergents

Sample diluent A – the defined protein (bovine serum albumin) matrix provided within the reagent kit for dilution of samples above the assay range

FastPack High Sensitivity C-Reactive Protein Calibrator Kit One level of calibrator material is provided ready to use in 1.0 mL/vial. Contains known quantities of human C-reactive protein. Contains $0 . 0 9 \%$ Sodium azide as preservative.

FastPack High Sensitivity C-Reactive Protein Control Kit Two levels of hsCRP controls are provided ready to use in $1 . 0 \ : \mathrm { m L / v i a l }$ . hsCRP controls are prepared from human plasma and human proteins. Preservatives $( 0 . 0 9 \%$ sodium azide) and stabilizers have been added to maintain product integrity.

FastPack High Sensitivity C-Reactive Protein Method Verification Kit Three levels (Low, Mid and High) are provided ready to use in 0.5 mL/vial. hsCRP Verifiers contain components of human origin prepared with protein stabilizers and preservatives to yield predetermined concentrations. Contains $0 . 0 9 \%$ sodium azide as preservative.

The Fast Pack High Sensitivity C-Reactive Protein Calibrator Kit, Controls and Verification

Kit contain human source material. Each serum/plasma donor unit used in the manufacture of these products has been tested by FDA accepted methods and found non-reactive for the presence of HBsAg and antibody to HIV-1/2, HCV and HIV-1 Ag.

# J. Substantial Equivalence Information:

1. Predicate device name(s):

· Olympus CRP Latex Reagent   
· Bio-Rad Laboratories Liquichek™ Cardiac Markers Plus Control Ortho-Clinical Diagnostics, Inc. VITRO Chemistry Products hsCRP Performance Verifier, I, II, and III

2. Predicate 510(k) number(s):

· k051564   
· k050537   
k041799

3. Comparison with predicate:

<table><tr><td colspan="3" rowspan="1">Similarities and Differences between FastPack and Olympus hsCRP Assays</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Qualigen FastPack HighSensitivity C-Reactive ProteinImmunoassay</td><td colspan="1" rowspan="1">Olympus America, Inc. CRPLatex reagentk051564</td></tr><tr><td colspan="1" rowspan="1">Intended Use/Indications for Use</td><td colspan="1" rowspan="1">High Sensitivity C-ReactiveProtein Immunoassay is to beused for evaluation ofconditions thought to beassociated with inflammation,in otherwise healthyindividuals.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Serum or plasma (EDTA orlithium heparin)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagent StorageTemperature</td><td colspan="1" rowspan="1">2-8 </td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Testing Environment</td><td colspan="1" rowspan="1">Professional use</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Precision (% CV)</td><td colspan="1" rowspan="1">Within-run: ≤ 1.0%Between-run: ≤ 5.2%Total: ≤9.0%</td><td colspan="1" rowspan="1">Within-run: ≤ 3.2%Total: ≤ 3.8%</td></tr><tr><td colspan="1" rowspan="1">Linearity</td><td colspan="1" rowspan="1">Assay linear from 0.2 mg/L to Assay linear from 0.2 - 160 mg/L15 mg/L in high sensitivityapplication</td><td colspan="1" rowspan="1">Assay linear from 0.2 mg/L to Assay linear from 0.2 - 160 mg/L</td></tr><tr><td colspan="1" rowspan="1">InterferingSubstances/Specificity</td><td colspan="1" rowspan="1">No interference found at thebelow tested concentrations:Bilirubin (conjugated) up to40 mg/dLBilirubin (unconjugated) up to40 mg/dLHemoglobin up to 750 mg/dLLipids up to 1000 mg/dLHuman serum albumin up to7.7 g/dLTransferrin up to 567 mg/dLHuman IgG up to 2961 µg/mL</td><td colspan="1" rowspan="1">No interference found at thebelow tested concentrations:Bilirubin up to 40 mg/dLHemoglobin up to 500 mg/dLIntralipid up to 1000 mg/dL</td></tr><tr><td colspan="1" rowspan="1">ExpectedValues/ReferenceIntervals</td><td colspan="1" rowspan="1">0.2 - 11.4 mg/L</td><td colspan="1" rowspan="1">Cardiac risk assessmentcategories:Low &lt; 1 mg/LAverage 1.0 to 3.0 mg/LHigh &gt; 3.0 mg/L</td></tr><tr><td colspan="1" rowspan="1">Methodology</td><td colspan="1" rowspan="1">The FastPack High SensitivityC-Reactive ProteinImmunoassay is aparamagnetic particle,chemiluminescentimmunoassay employingspecific murine monoclonalantibodies.</td><td colspan="1" rowspan="1">The Olympus CRP Latex reagentis a turbidimetric assay employingrabbit antibodiescoated on latex particles.</td></tr><tr><td colspan="1" rowspan="1">Assay principle</td><td colspan="1" rowspan="1">Chemiluminescence</td><td colspan="1" rowspan="1">Turbidimetry</td></tr><tr><td colspan="1" rowspan="1">Assay procedure</td><td colspan="1" rowspan="1">Automated</td><td colspan="1" rowspan="1">Automated</td></tr><tr><td colspan="1" rowspan="1">Assay range</td><td colspan="1" rowspan="1">0.2 - 15 mg/L for HighSensitivity Application</td><td colspan="1" rowspan="1">0.2 - 160 mg/L (providesmeasurements both for "NormalApplication" and "HighlySensitive Application")</td></tr><tr><td colspan="1" rowspan="1">Traceability</td><td colspan="1" rowspan="1">Traceable to the ERM-DA474/IFCC reference whichserves as the PrimaryReference Material</td><td colspan="1" rowspan="1">Traceable to an externalstandard</td></tr></table>

<table><tr><td colspan="3">Similarities and Differences between FastPack and Olympus CRP Calibrators</td></tr><tr><td>Item</td><td>Qualigen FastPack High-Sensitivity C- Reactive Protein Immunoassay</td><td>Olympus America, Inc. CRP Latex reagent k051564</td></tr><tr><td colspan="1" rowspan="1">IntendedUse/Indication forUse</td><td colspan="1" rowspan="1">For in-vitro diagnosticuse in calibratingC-Reactive ProteinImmunoassay</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Antigen used in</td><td colspan="1" rowspan="1">Human CRP</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Liquid human serum matrixcontaining a predeterminedlevel of human CRP</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Storage temperature</td><td colspan="1" rowspan="1">2-8 </td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Number of calibrators</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">5 (additional calibrators providedat higher concentrations toenable CRP measurements in the"Normal Application"</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Similarities and Differences between FastPack and Predicate CRP Controls</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Qualigen FastPack High-Sensitivity C-Reactive ProteinImmunoassay</td><td colspan="1" rowspan="1">Bio-Rad LaboratoriesLiquichek™M Cardiac MarkersPlus Controlk050537</td></tr><tr><td colspan="1" rowspan="1">IntendedUse/Indication forUse</td><td colspan="1" rowspan="1">For in-vitro diagnostic use tomonitor the precision andaccuracy of the High-Sensitivity C-Reactive Protein</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Antigen used incontrols</td><td colspan="1" rowspan="1">Human CRP</td><td colspan="1" rowspan="1">B-type Natriuretic Peptide,Creatine Kinase (Total), C-Reactive Protein, Homocysteine,Digitoxin, N-terminal pro-B-typeNatriuretic Peptide, CK-MB,Myoglobin, Troponin I, TroponinT</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Liquid human serum matrixcontaining apredetermined level of humanCRP</td><td colspan="1" rowspan="1">Prepared from human serum withadded constituents of human andanimal origin, preservatives, andstabilizers. The controls are inliquid form.</td></tr><tr><td colspan="1" rowspan="1">Storage temperature</td><td colspan="1" rowspan="1">2-8 °C</td><td colspan="1" rowspan="1">2-8 °C (Opened), or -20 to -70 °C(Unopened)</td></tr><tr><td colspan="1" rowspan="1">Number of levels</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="3" rowspan="1">Similarities And Differences between FastPack CRP Verifiers and Predicate Verifiers</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Qualigen FastPack High-Sensitivity C-Reactive ProteinImmunoassay</td><td colspan="1" rowspan="1">Ortho-Clinical Diagnostics, Inc.VITRO Chemistry ProductshsCRP Performance Verifier, I,II, and III k041799</td></tr><tr><td colspan="1" rowspan="1">IntendedUse/Indication forUse</td><td colspan="1" rowspan="1">For use in the quantitativeverification of calibrationand assay range of the High-Sensitivity C-Reactive Protein.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Antigen used</td><td colspan="1" rowspan="1">Human CRP</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Storage temperature</td><td colspan="1" rowspan="1">2-8 °</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Low Verifier: HEPESbuffer with Bovine SerumAlbumin (BSA) andDetergentMid and High Verifiers:Liquid human serum matrixcontaining a predeterminedlevel of human CRP</td><td colspan="1" rowspan="1">A base matrix of humanplasma proteins to whichstabilizers and preservativehave been added.</td></tr><tr><td colspan="1" rowspan="1">Number of levels</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">Same</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP5-A2: Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline, Second Edition, 2005 CLSI EP6-A: Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline 2014   
· CLSI EP7-A2: Interference Testing in Clinical Chemistry, Approved Guideline, Second Edition, 2014   
C CLSI EP9-A3: Method Procedure Comparison and Bias Estimation Using Patient Samples; Approved Guideline, Third Edition 2014 CLSI EP14-A2: Evaluation of Matrix Effects; Approved Guideline, Second Edition 2014 CSLI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline, Second Edition 2013 CLSI EP28-A3c: Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline, Third Edition 2014 CLSI-I/LA21-A2: Clinical Evaluation of Immunoassays; Approves Guideline, Second Edition 2008

· CLSI-I/LA30-A: Immunoassay Interference by Endogenous Antibodies; Approved Guideline 2009

# L. Test Principle:

The FastPack High Sensitivity C-Reactive Protein Immunoassay employs a Sandwich immunoassay principle. Endogenous CRP in a patient sample, calibrator, control, or verifier is dispensed into a FastPack reagent pack. In the reagent pack, the sample binds with a murine monoclonal anti-CRP antibody covalently linked to alkaline phosphatase (ALP) and a different murine monoclonal anti-CRP antibody linked to biotin. After incubation, immunoreacted complex (Monoclonal anti-CRP antibody-ALP conjugate and anti-CRP antibody linked to biotin reacted with CRP in the sample) is mixed with streptavidin coated paramagnetic particles. After washing steps (using a Tris buffer containing detergents) to separate bound from unbound anti-CRP monoclonal antibody-ALP, a chemiluminogenic substrate mixture is added to the system. This mixture contains indoxyl-3-phosphate, a substrate for ALP, and lucigenin (N,N’- dimethyl- $^ { 9 , 9 }$ -biacridinium dinitrate). ALP dephosphorylates indoxyl-3-phosphate to indol-3-ol, which subsequently undergoes oxidation. As a result, lucigenin is reduced to form a dioxetane structure that is cleaved to yield N-methylacridone. This compound produces a sustained luminescent glow following excitation. The raw relative luminescence units (RLUs) generated are measured by a photomultiplier tube in the FastPack Analyzer and are directly proportional to the concentration of CRP in the sample.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

# a. Precision/Reproducibility:

Precision was evaluated following the CLSI EP5-A2 guidance. Six serum patient samples with concentrations of 0.5, 1.0, 2.5, 5.0, 7.5 and $1 2 . 5 ~ \mathrm { m g / L }$ CRP were tested in duplicate determinations in each of two runs per day on each of two FastPack Reagent lots, two FastPack Analyzers per reagent lot, over a period of 20 days to yield 320 replicate determinations of each sample. A single FastPack calibrator lot was utilized for all runs. Within-run, between-run, and between-day components of variation were calculated and total imprecision using general linear model (GLM). The table below presents the results:

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Average</td><td rowspan=1 colspan=2>Within-run</td><td rowspan=1 colspan=2>Between-run</td><td rowspan=1 colspan=2>Between-day</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.38</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>0.53</td><td rowspan=1 colspan=1>0.014</td><td rowspan=1 colspan=1>3.68</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>1.32</td><td rowspan=1 colspan=1>0.033</td><td rowspan=1 colspan=1>8.68</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>0.43</td><td rowspan=1 colspan=1>0.038</td><td rowspan=1 colspan=1>3.80</td><td rowspan=1 colspan=1>0.013</td><td rowspan=1 colspan=1>1.30</td><td rowspan=1 colspan=1>0.087</td><td rowspan=1 colspan=1>8.70</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2.06</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>0.39</td><td rowspan=1 colspan=1>0.071</td><td rowspan=1 colspan=1>3.45</td><td rowspan=1 colspan=1>0.030</td><td rowspan=1 colspan=1>1.46</td><td rowspan=1 colspan=1>0.180</td><td rowspan=1 colspan=1>8.74</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>5.01</td><td rowspan=1 colspan=1>0.023</td><td rowspan=1 colspan=1>0.46</td><td rowspan=1 colspan=1>0.206</td><td rowspan=1 colspan=1>4.11</td><td rowspan=1 colspan=1>0.073</td><td rowspan=1 colspan=1>1.46</td><td rowspan=1 colspan=1>0.362</td><td rowspan=1 colspan=1>7.23</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>7.67</td><td rowspan=1 colspan=1>0.035</td><td rowspan=1 colspan=1>0.46</td><td rowspan=1 colspan=1>0.314</td><td rowspan=1 colspan=1>4.09</td><td rowspan=1 colspan=1>0.111</td><td rowspan=1 colspan=1>1.45</td><td rowspan=1 colspan=1>0.684</td><td rowspan=1 colspan=1>8.92</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>12.54</td><td rowspan=1 colspan=1>0.073</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>0.649</td><td rowspan=1 colspan=1>5.18</td><td rowspan=1 colspan=1>0.230</td><td rowspan=1 colspan=1>1.83</td><td rowspan=1 colspan=1>1.091</td><td rowspan=1 colspan=1>8.70</td></tr></table>

# b. Linearity/assay reportable range:

# Linearity:

This linearity study followed CLSI EP6-A. A high patient sample was intermixed with a low sample to generate 8 concentration levels each tested in triplicate determinations using one FastPack reagent lot on one FastPack analyzer using one FastPack calibrator lot. Linear results were compared to 2nd and 3rd order polynomial fits against a pre-specified allowable error. The linearity range was found to extend from the LOQ $( 0 . 0 6 3 \mathrm { m g / L } )$ to $1 5 . 0 \mathrm { m g / L }$ .

The linear fit yields an equation of $\mathbf { y } = 0 . 0 0 + 0 . 9 7 \mathbf { x }$ with percent deviation from linearity of $\leq \pm 1 0 \%$ .

Samples recovering above the range may be diluted using Sample Diluent A.   
Dilutional linearity has been validated by the sponsor in their Hook effect study.

# Hook effect:

Four patient serum samples with endogenous values of approximately 450, 300, 300, and $4 0 0 \mathrm { m g / L }$ , respectively were run neat and diluted 1:100 in Sample Diluent A in triplicate determinations using one FastPack Reagent lot, one calibrator lot on two FastPack Analyzers. The objective of the study was to demonstrate that the Neat values exceeded the upper limit of the assay $( 1 5 \mathrm { m g / L } )$ .

The results demonstrate that all high level samples recover $> 1 5 ~ \mathrm { m g / L }$ when run neat (range: $2 1 . 5 1 - 3 5 . 0 3 \mathrm { m g / L } )$ and that back calculated actual values range from 309.5 - $4 4 2 . 6 \mathrm { m g / L }$ CRP.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

The sponsor bases its traceability process for hsCRP on the International Standard prEN ISO 17511:2003, Metrological Traceability of Values Assigned to Calibrator and Control Material. It is traceable to the ERMDA474/IFCC reference which serves as the Primary Reference Material. The value assignment process for calibrators, controls and verifiers was reviewed and found to be adequate.

Shelf Life and Open Vial Stability for Calibrators:

The FastPack calibrator materials have a shelf life stability of 12 months stored at 2- $8 ^ { \circ } \mathrm { C }$ , and have open-vial stability of 30 days when stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ .

Shelf Life and Open Vial Stability for Controls and Verifiers:

The FastPack controls and verifiers have a shelf life stability of 24 months stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ , and have open-vial stability of 30 days when stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ .

The stability study protocols and acceptance criteria were reviewed and found to be adequate.

The limit of blank (LOB), limit of detection (LOD), and limit of quantitation (LOQ) were determined according to CLSI EP17.

# LoB:

In this study, the limit of blank was determined from 80 replicate determinations of a blank sample tested on four different FastPack instruments using two reagent lots. The LOB was determined as the upper 95th percentile of the distribution. This value was $0 . 0 0 5 \mathrm { m g / L }$ CRP.

# LoD:

The LOD was estimated from 80 replicate determinations of three low samples. Per the CLSI EP17-A guideline, LOD was determined by the following equation: $\mathrm { L O D } = \mathrm { L O B } + ( \mathrm { c } \mathrm { B } ^ { \ast } \mathrm { S D S } )$ ,   
where ${ \mathrm { c B } } = 1 . 6 4 5 / ( 1 { \cdot } ( 1 / ( 4 ^ { * } { \mathrm { f } } ) )$ , where f is the degrees of freedom, and SDS is the pooled standard deviation of the observations. In this study, the LOD was found to be $0 . 0 3 2 \mathrm { m g / L }$ CRP.

# $\underline { { \mathrm { L o Q } } } \mathrm { : }$

The LoQ was determined as the lowest sample which provided $< 2 0 \%$ CV. The LOQ was set to $0 . 0 6 3 \mathrm { m g / L }$ CRP.

# e. Analytical specificity:

Endogenous substance interference was evaluated by spiking two serum samples (1.0 and $6 . 0 \mathrm { m g / L }$ CRP, respectively) with hemoglobin, lipid, bilirubin, albumin, rheumatoid factor (RF), transferrin, human anti-mouse IgG HAMA and Heterophile/HAMA. The samples testing interference with hemoglobin, lipid, bilirubin, albumin, rheumatoid factor (RF), transferrin were analyzed in 5 replicate determinations using one FastPack analyzers and one lot of Fast Pack reagents. The samples testing interference with human anti-mouse IgG HAMA were tested in duplicate and samples testing interference with Heterophile/HAMA in triplicate determinations, respectively. There was no significant interference for the following endogenous substances in the ranges tested below:

Bilirubin up to $4 0 \mathrm { m g / d L }$   
Hemoglobin up to $7 5 0 \mathrm { m g / d L }$   
Lipids up to $1 0 0 0 \mathrm { m g / d L }$   
Albumin up to $7 . 7 \ : \mathrm { g / d L }$   
Rheumatoid factor (RF) up to $1 0 0 0 \ : \mathrm { I U / m L }$ Transferrin up to $5 6 7 \mathrm { m g / d L }$   
Human IgG up to $2 9 6 1 ~ \mu \mathrm { g / m L }$   
Human anti-mouse IgG HAMA up to $4 \mathrm { m g / d L }$ Heterophile/HAMA up to $3 6 4 1 ~ \mathrm { n g / m l L }$ .

The sponsor also tested potential interference to the exogenous substances in 5 replicate determinations using one FastPack analyzer and one lot of Fast Pack reagents. No significant interference was found when these substances were tested in the concentration ranges indicated below:

L-Ascorbic Acid up to $2 0 0 \mathrm { m g / L }$ Oxaloacetic Acid up to $3 0 0 \mu \mathrm { M }$ Glutathione up to $3 0 0 \mu \mathrm { M }$ Isoniazid up to $3 0 0 \mu \mathrm { M }$ L-DOPA up to $3 0 0 \mu \mathrm { M }$

The sponsor’s definition of non-significant interference is $< 1 0 \%$ difference between the spiked and unspiked samples.

The labeling includes a limitation that heterophilic antibodies may interfere with this method.

f. Assay cut-off:

Not applicable

2. Comparison studies:

a. Method comparison with predicate device:

In this method comparison study, one hundred and thirty three human serum samples with CRP values across the measuring range were analyzed on the candidate device and the results were compared to those determined with the predicate device. Deming regression results from the method comparison study are summarized in the table below:

<table><tr><td rowspan=1 colspan=1>No. Samples</td><td rowspan=1 colspan=1>Range Tested(mgl/L)</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>y-intercept(95% CI)</td><td rowspan=1 colspan=1>R(95% CI)</td></tr><tr><td rowspan=1 colspan=1>143</td><td rowspan=1 colspan=1>0.21 - 15.00</td><td rowspan=1 colspan=1>0.98(0.95-1.01)</td><td rowspan=1 colspan=1>-0.12(-0.21 to -0.02)</td><td rowspan=1 colspan=1>0.99(0.99 - 0.99)</td></tr></table>

b. Matrix comparison:

Serum and lithium-heparin plasma

The sponsor performed a matrix comparison study to assess the performance of the assay when different sample types/tubes (serum vs. EDTA plasma and. Lithium Heparin plasma) were tested. Forty one human blood samples were processed to serum, lithium-heparin plasma, or EDTA plasma in parallel. The samples were then tested in duplicate determinations each in the FastPack High Sensitivity C-Reactive Protein Immunoassay using two lots of FastPack Reagents and one lot of calibrators. The data analysis was performed using singlicate results. Deming regression results for comparisons of EDTA and lithium-heparin plasma to serum are summarized in tables below:

# Comparison of serum and EDTA plasma:

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>N compared</td><td rowspan=1 colspan=1>41</td></tr><tr><td rowspan=1 colspan=1>Range of observations, mg/L</td><td rowspan=1 colspan=1>Serum: 0.33 - 14.72EDTA Plasma: 0.29 - 14.76</td></tr><tr><td rowspan=1 colspan=1>Absolute bias, mg/L</td><td rowspan=1 colspan=1>-0.225</td></tr><tr><td rowspan=1 colspan=1>% Bias</td><td rowspan=1 colspan=1>-6.1</td></tr><tr><td rowspan=1 colspan=1>Deming regression results</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.94</td></tr><tr><td rowspan=1 colspan=1>y-intercept</td><td rowspan=1 colspan=1>0.0</td></tr><tr><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>0.984</td></tr><tr><td rowspan=1 colspan=1>R2</td><td rowspan=1 colspan=1>0.967</td></tr></table>

# Comparison of serum and Lithium-Heparin plasma:

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>N compared</td><td rowspan=1 colspan=1>41</td></tr><tr><td rowspan=1 colspan=1>Range of observations, mg/L</td><td rowspan=1 colspan=1>Serum: 0.33 - 14.72Lithium-Heparin Plasma: 0.31 - 14.86</td></tr><tr><td rowspan=1 colspan=1>Absolute bias, mg/L</td><td rowspan=1 colspan=1>0.002</td></tr><tr><td rowspan=1 colspan=1>% Bias</td><td rowspan=1 colspan=1>0.5</td></tr><tr><td rowspan=1 colspan=2>Deming regression results</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>1.00</td></tr><tr><td rowspan=1 colspan=1>y-intercept</td><td rowspan=1 colspan=1>0.00</td></tr><tr><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>0.993</td></tr><tr><td rowspan=1 colspan=1>R2</td><td rowspan=1 colspan=1>0.986</td></tr></table>

The studies support the sponsor’s claims that EDTA and Lithium-Heparin are acceptable anticoagulants to be used with The FastPack hsCRP Assay.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable   
b. Clinical specificity: Not applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range:

A reference interval study was carried out with serum samples from 211 subjects representing 4 different geographic regions of the United States yielded the results in the table below. The non-parametric 2.5th - 97.5th percentile of $0 . 2 \textrm { - } 1 1 . 4 \ : \mathrm { m g / L }$ provides the reference interval determined from this study, which is in accord with literature1-4.

<table><tr><td rowspan=1 colspan=2>Observed values</td></tr><tr><td rowspan=1 colspan=1>Mean (SD)</td><td rowspan=1 colspan=1>3.2 (3.1) mg/L</td></tr><tr><td rowspan=1 colspan=1>Median (Min - Max)</td><td rowspan=1 colspan=1>1.9 (0.2 - 13.1) mg/L</td></tr><tr><td rowspan=1 colspan=1>2.5th - 97.5th percentile</td><td rowspan=1 colspan=1>0.2 - 11.4 mg/L</td></tr></table>

Newborns with no evidence of infection have CRP concentrations $\mathrm { { ^ { o f < 2 } m g / L } }$ .5

# References:

1 Aziz N, Fahey JL, Detels R, Butch AW. Analytical performance of a highly sensitive C-reactive protein-based immunoassay and the effects of laboratory variables on levels of protein in blood. Clinical and Diagnostic Laboratory Immunology 2003;10:652-7.   
2 Imhof A, Frohlich M, Loewel H, et al. Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe. Clin Chem 2003;49:669-72.   
3 Sennels HP, Jacobsen S, Jensen T, et al. Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein. Scand J Clin Lab Invest 2007;67:821-35.   
4 Charuruks N, Laohajinda B, Rujiwanitgun S, Chaiworaporn M. Reference interval for C-reactive protein and its distribution pattern in thai adults. Circ J 2005;69:339-44.   
5 Soldin OP, Bierbower LH, Choi JJ, et al. Serum iron, ferritin, transferrin, total iron

binding capacity, hs-CRP, LDL cholesterol and magnesium in children; new reference intervals using the Dade Dimension Clinical Chemistry System; Clin Chim Acta 2004;342:211-7.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.